Biovie (BIVI) Shares Outstanding (2013 - 2026)
Biovie (BIVI) posted Shares Outstanding (Entity) of $7.5 million for Q1 2026, little changed sequentially from $7.5 million in Q4 2025, and up 306.81% YoY from $1.9 million in Q1 2025.
Biovie (BIVI) Shares Outstanding (2013 - 2026) Analysis & Trends
Biovie has reported Shares Outstanding (Entity) for 14 years, with the latest figure at $7.5 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 306.81% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.5 million (up 306.81% YoY) and the FY2025 annual result came in at $1.5 million, up 226.96% from the prior year.
- Shares Outstanding (Entity) was little changed at $7.5 million in Q1 2026 per BIVI's latest filing, from $7.5 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $7.5 million in Q1 2026 and troughed at $249841.0 in Q1 2022.
- A 5-year average of $1.7 million and a median of $448011.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Entity) grew 15.54% in 2023, then soared 714.95% in 2025.
- Over 5 years, Shares Outstanding (Entity) stood at $345043.0 in 2022, then advanced by 15.54% to $398667.0 in 2023, then surged by 363.5% to $1.8 million in 2024, then surged by 308.24% to $7.5 million in 2025, then advanced by 0.01% to $7.5 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $7.5 million, $7.5 million, and $5.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | 7.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.54 Mn |
| Mar 31, 2026 | 7.54 Mn |
| Dec 31, 2025 | 7.92 Mn |
| Sep 30, 2025 | 5.21 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 1.85 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 639,836.00 |
| Jun 30, 2024 | 451,853.00 |
| Mar 31, 2024 | 448,011.00 |
| Dec 31, 2023 | 381,708.00 |
| Sep 30, 2023 | 367,428.00 |
| Jun 30, 2023 | 324,835.00 |
| Mar 31, 2023 | 353,256.00 |
| Dec 31, 2022 | 311,688.00 |
| Sep 30, 2022 | 272,124.00 |
| Jun 30, 2022 | 246,626.00 |
| Mar 31, 2022 | 249,841.00 |
| Dec 31, 2021 | 249,624.00 |
| Sep 30, 2021 | 237,199.00 |